Skip to content
Search

Latest Stories

Bas Vorsteveld to leave Haleon at year’s end

Bas Vorsteveld to leave Haleon at year’s end

He has been with Haleon since its creation, which resulted from the combination of three consumer health businesses

Haleon's vice-president and general manager for Great Britain and Ireland, Bas Vorsteveld, has announced his departure from the company.

Vorsteveld had been with Novartis Consumer Health and GSK since 2016, serving in various roles before the creation of Haleon.


“It's a wrap. After a journey of nearly 19 amazing years, I will be leaving Haleon at the end of this year to start a new chapter.

“Will be leaving a company that massively changed over time from the moment I started at Novartis Consumer Health. Did lead my teams through two integrations with GSK & Pfizer CH before separating,” he posted on LinkedIn.

He has not disclosed his next move but mentioned that he will share more about his future in the coming months.

Vorsteveld has also been serving as the president of the consumer healthcare association, PAGB, since December 2022.

Haleon is the culmination of the integration of three consumer health businesses, GlaxoSmithKline plc (GSK), Novartis, and Pfizer over the past decade. The company demerged from GSK in July 2022 and became an independent entity listed on the London and New York stock exchanges.

This year, Haleon won the Pharmacy Business Award for Branded Manufacturer of the Year, Vorsteveld receiving the award from pharmacy minister Stephen Kinnock.

Pharmacy Business award Left to Right: Shailesh Solanki, Bas Vorsteveld, VP and General Manager for GB&I, Haleon, Stephen Kinnock MP, Kalpesh Solanki and Rory Bremner

Upon winning the award, he expressed: “Always great if the hard work of the team is being recognized.

We would like to thank all the pharmacists for their confidence and recognition of our strong partnerships and the way we deliver everyday health with humanity together.

Big thanks to my fantastic leadership team, who make the difference on a daily base for their teams, our customers and consumers in GBI.”

He noted that self-care has a lot of opportunities to help the government to relief the pressure on the NHS, with pharmacists playing a crucial role in this effort.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less